Upgrade to SI Premium - Free Trial

Vor Biopharma (VOR) Reiterated at Buy by Stifel After Meetings About Telitacicept Potential

April 8, 2026 7:24 AM
Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Vor Biopharma, Inc. (NASDAQ: VOR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments